SHAIL RAKESH MODI, TERRICK ANDEY^*

Oncology Research, Vol.32, No.11, pp. 1709-1721, 2024, DOI:10.32604/or.2024.053972 - 16 October 2024

Abstract Objectives: EGFR tyrosine kinase inhibitor (EGFR-TKI) therapies such as erlotinib and gefitinib are approved for the treatment of non-small cell lung cancer (NSCLC). However, the high incidence of acquired resistance to these EGFR-TKIs may preclude their effectiveness. Piperlongumine (PPL), an extract from the long pepper fruit (Piper longum), has been shown to possess anticancer properties. The purpose of the study was to investigate piperlongumine as an anticancer agent and to study a combination treatment approach with EGFR-TKIs against lung cancer cells. Methods: Anticancer efficacy of PPL, erlotinib (ERL), gefitinib (GEF), and cisplatin (CIS) were investigated in… More >

ZHIGUO WANG^1,2,#, KUNLIN LI^2,#, CONGHUA LU², MINGXIA FENG², CAIYU LIN², GUOFANG YIN¹, DAN LUO¹, WENYI LIU³, KAIYU JIN⁴, YUANYAO DOU², DI WU², JIE ZHENG², KEJUN ZHANG⁵, LI LI^2,*, XIANMING FAN^1,*

Oncology Research, Vol.32, No.10, pp. 1637-1648, 2024, DOI:10.32604/or.2024.052664 - 18 September 2024

Abstract Background: Metformin has pleiotropic effects beyond glucose reduction, including tumor inhibition and immune regulation. It enhanced the anti-tumor effects of programmed cell death protein 1 (PD-1) inhibitors in serine/threonine kinase 11 (STK11) mutant non-small cell lung cancer (NSCLC) through an axis inhibition protein 1 (AXIN1)-dependent manner. However, the alterations of tumor metabolism and metabolites upon metformin administration remain unclear. Methods: We performed untargeted metabolomics using liquid chromatography (LC)-mass spectrometry (MS)/MS system and conducted cell experiments to verify the results of bioinformatics analysis. Results: According to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database, most… More > Graphic Abstract

WEN GE^1,2,#, YA LI^1,2,#, YUTING RUAN^1,2, NINGXIA WU^1,2, PEI MA^3,4, TONGPENG XU^3,4, YONGQIAN SHU^3,4, YINGWEI WANG^1,2, WEN QIU^1,2, CHENHUI ZHAO^3,4,*

Oncology Research, Vol.32, No.4, pp. 625-641, 2024, DOI:10.32604/or.2023.031053 - 20 March 2024

Abstract The cancer cell metastasis is a major death reason for patients with non-small cell lung cancer (NSCLC). Although researchers have disclosed that interleukin 17 (IL-17) can increase matrix metalloproteinases (MMPs) induction causing NSCLC cell metastasis, the underlying mechanism remains unclear. In the study, we found that IL-17 receptor A (IL-17RA), p300, p-STAT3, Ack-STAT3, and MMP19 were up-regulated both in NSCLC tissues and NSCLC cells stimulated with IL-17. p300, STAT3 and MMP19 overexpression or knockdown could raise or reduce IL-17-induced p-STAT3, Ack-STAT3 and MMP19 level as well as the cell migration and invasion. Mechanism investigation revealed… More > Graphic Abstract

ZHONGXIANG TANG^1,2, LILI WANG^1,2, GUOJUN WU^1,2, LING QIN^1,2,*, YURONG TAN^1,2,*

BIOCELL, Vol.47, No.11, pp. 2503-2516, 2023, DOI:10.32604/biocell.2023.031565 - 27 November 2023

Abstract Background: Non-small cell lung cancer (NSCLC) has a poor prognosis with a low 5-year survival rate. Lung adenocarcinoma (LUAD) accounts for 50%. Facio-genital dysplasia-5 (FGD5), a member of a subfamily of Rho GTP-GDP exchange factors, may be a good molecular biomarker for diagnosis and prognosis. Objective: To explore the clinical application of FGD5, the study was designed to investigate the prognosis value of FGD5 expression and its correlation with immune infiltrates in LUAD patients. Methods: Through the Wilcoxon signed-rank test and logistic regression, the correlation between clinical characteristics and FGD5 expression was analyzed. Kaplan–Meier plotter analysis,… More > Graphic Abstract

NAN TANG^1,#, YAJING ZHAN^1,#, JIAYAN MAO^2,#, ANKANG YIN¹, WEI WANG^3,*, JUAN WANG^3,*

BIOCELL, Vol.47, No.9, pp. 2009-2026, 2023, DOI:10.32604/biocell.2023.029269 - 28 September 2023

Abstract Non-small cell lung cancer (NSCLC) is a malignant tumor with high incidence worldwide. Triptolide (TP), extracted from Tripterygium wilfordii Hook F, exhibits potent broad-spectrum antitumor activity. Although some mechanisms through which TP inhibits NSCLC are well understood, those that involve ribosomal proteins remain yet to be understood. In this study, the transcriptome and proteome were integrated and analyzed. Our data indicated ribosomal protein L4 (RPL4) to be a core hub protein in the protein-protein interaction network. RPL4 is overexpressed in NSCLC tissues and cells. Transfection with siRPL4 or TP treatment alone arrested the cell cycle in More > Graphic Abstract

WEI DU¹, FANG YIN¹, YATING ZHONG¹, MINJIE LUO¹, ZHEN WANG², PENG LIN², QING LIU^2,*, HAN YANG^2,*

Oncology Research, Vol.31, No.6, pp. 929-936, 2023, DOI:10.32604/or.2023.030611 - 15 September 2023

Abstract Non-small cell lung cancer (NSCLC) is a highly lethal cancer, and better treatments are urgently needed. Many studies have implicated circular RNAs (circRNAs) in the progression of multiple malignant tumors. Nonetheless, the functions of circRNAs in NSCLC remain unclear. To study new targets for the treatment of NSCLC, circRNA expression profiling was performed on NSCLC tissues and para-carcinoma nonmalignant tissues. RNA was isolated and used for circRNA sequencing. Biological studies were performed in vitro and in vivo to determine the functions of circRNAs in NSCLC, including their functions in cell proliferation and migration. How circRNAs function in More > Graphic Abstract

LU LIU^1,2, BIN XIE^1,2, WEI ZHU^1,2, QIUYAN HE^1,2, JIANHUA ZHOU^1,2, SHUANG LIU³, YONGGUANG TAO⁴, DESHENG XIAO^1,2,*

Oncology Research, Vol.31, No.3, pp. 275-286, 2023, DOI:10.32604/or.2023.028227 - 22 May 2023

Abstract Background: Lung cancer is one of the most lethal cancers worldwide, but studies have shown that the higher the expression of programmed cell death protein 1 ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC), the more likely it will benefit from anti-PD-L1 immunotherapy. The purpose of our study was to collect and analyze abundant clinical samples in order to provide evidence for clinicians and patients who might consider anti-PD-L1 immunotherapy while jointly formulating treatment plans. Methods: On the one hand, we obtained cases from The Cancer Genome Atlas (TCGA) database, including 498 lung squamous… More >

XIANGCHAO DING^1,#, YANG ZHAO^2,#, XINGHUA ZHANG¹, HUIQING LIN^1,*

BIOCELL, Vol.47, No.5, pp. 1117-1126, 2023, DOI:10.32604/biocell.2023.026715 - 10 April 2023

Abstract Background: Long-chain non-coding RNA (lncRNA) LINC00609 is a potential tumor suppressor, but the mechanism of action in non-small cell lung cancer (NSCLC) is yet to be understood.Objectives: The effects of LINC00609 on A549 cell proliferation, apoptosis, and cell cycle arrest were investigated. Methods: The LINC00609 levels in NSCLC and normal tissues were analyzed by bioinformatics. Expressions of LINC00609, miR-128-3p, and Rho family GTPase 3 (RND3) in NSCLC cells (A549) were determined by qRT-PCR. Bioinformatics analysis predicted target genes and dual-luciferase reporter assays to ensure that LINC00609 targeted miR-128-3p and miR-128-3p targeted RND3. The proliferation of cells was… More >

Jiajian Shi¹, Yuchen Chen^1,*, Chentai Peng¹, Linwu Kuang², Zitong Zhang¹, Yangkai Li^2,*, Kun Huang¹

Oncologie, Vol.24, No.4, pp. 613-648, 2022, DOI:10.32604/oncologie.2022.027545 - 31 December 2022

Abstract The incidence and mortality of lung cancer rank top three of all cancers worldwide. Accounting for 85% of the total number of lung cancer, non-small cell lung cancer (NSCLC) is an important factor endangering human health. Recently, targeted therapies against driver mutations and epigenetic alterations have made encouraging advances that benefit NSCLC patients. Druggable driver mutations, which mainly occur in EGFR, KRAS, MET, HER2, ALK, ROS1, RET and BRAF, have been identified in more than a quarter of NSCLC patients. A series of highly selective mutant targeting inhibitors, such as EGFR tyrosine kinase inhibitors and KRAS inhibitors, have been… More >

Li Xu, Kang Li, Jia Li, Liyu Liu, Fang Xu, Yan Xu, Yi Kong, Xingxiang Pu, Qianzhi Wang, Jingyi Wang, Bolin Chen^*, Lin Wu^*

Oncologie, Vol.24, No.3, pp. 579-590, 2022, DOI:10.32604/oncologie.2022.022121 - 19 September 2022

Abstract Background: Non-small cell lung cancer (NSCLC), caused by abnormal gene drive, may have primary drug resistance after treatment with tyrosine kinase inhibitors (EGFR-TKIs). Therefore, we explore whether the primary drug-resistant NSCLC treated with EGFR-TKI is related to the miR-21/Sonic Hedgehog (SHH)/PI3K/AKT pathway. Methods: The patients from our hospital who meet the AJCC TNM staging (7th edition) stage IIIB and stage IV NSCLC were selected in this case study. Thereafter, the treatment response of EGFR-TKIs was evaluated according to the solid tumor efficacy evaluation standard (version 1.1). The patients were divided into the EGFR-TKIs primary drug resistance group… More >